Company news

Acurx Pharmaceuticals, Inc. news in 2025

Acurx Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

November 18, 2025

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

November 12, 2025

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

November 10, 2025

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

October 28, 2025

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

October 27, 2025

Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC

October 10, 2025

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

October 9, 2025

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

September 30, 2025

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events

September 5, 2025

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

September 3, 2025

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

August 12, 2025

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

July 31, 2025

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

July 24, 2025

Correction: Acurx Pharmaceuticals, Inc.

June 16, 2025

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

June 17, 2025

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

June 9, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

May 13, 2025

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

April 30, 2025

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

April 28, 2025

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

April 17, 2025

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

March 18, 2025

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

March 10, 2025

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

March 7, 2025

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

March 3, 2025

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

February 28, 2025

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

February 24, 2025

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

February 19, 2025

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

January 5, 2025

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 5, 2025

Calls in 2025

Decks in 2025